Medtronic gains rights to Angeion ICD patents through arbitrator's decision; Angeion considers legal action.
This article was originally published in The Gray Sheet
ANGEION WEIGHS RESPONSE TO AWARDING OF ICD PATENTS TO MEDTRONIC by arbitrator William Webster of the Washington D.C. law firm Milbank, Tweed, Hadley & McCloy. Webster's decision resolves a patent licensing dispute brought by Pacesetter parent St. Jude against Medtronic in 1995. Pacesetter obtained rights to Angeion's implantable cardioverter defibrillator patents in 1993 ("The Gray Sheet" March 22, 1993, In Brief).
You may also be interested in...
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.
US FDA Will Need About A Week To Complete COVID Vaccine Assessment Following Advisory Cmte., CBER’s Marks Says
Timeline is the most pessimistic public projection to date, but still incredibly fast. Clinical trial patients on placebo could be contacted and offered the vaccine after an EUA is granted.